Mantle cell lymphoma (MCL) is a cancer of B-lymphocytes located in regions named mantle zones in the lymph nodes. Mantle cell lymphomas are quite rare, representing 5% to 7% of all lymphomas non-Hodgkin diagnosed in Western countries.

CAR-Ts are innovative therapies that offer a real hope of treatment for patients diagnosed with B-cell lymphoma, including MCL.

A project initiated by Dr Charles Herbaux at the Montpellier University Hospital aims to better understand the efficacy and safety of CAR T-cells for patients diagnosed with MCL.

Analyses for this project are performed by the LYSARC, using data from patients included in the DESCAR-T registry before July 2021 and diagnosed with mantle cell lymphoma.

To the patients that received CAR-T, if you would like more information about the treatment of your data in the DESCAR-T Registry, you can contact the doctor at your centre of care for your CAR-T treatment or make a request at dpo@lysarc.org. You can find more details your rights regarding your data in the section “I am participating or have participated in a clinical trial“, or in the Patient Information Leaflet you received at the time of your inclusion in the registry.